Two selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, are FDA-approved for the primary prevention of breast cancer—tamoxifen for both pre- and post-menopausal women, and raloxifene for post-menopausal women only [1•, 2]. The gene discussed is ESR1; the disease is breast carcinoma.